Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.

Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kupčinskas J, Fumery M, Gower-Rousseau C, Lakatos L, Lakatos PL, D'Incà R, Sartini A, Valpiani D, Giannotta M, Arebi N, Duricova D, Bortlik M, Chetcuti Zammit S, Ellul P, Pedersen N, Kjeldsen J, Midjord JMM, Nielsen KR, Winther Andersen K, Andersen V, Katsanos KH, Christodoulou DK, Domislovic V, Krznaric Z, Sebastian S, Oksanen P, Collin P, Barros L, Magro F, Salupere R, Kievit HAL, Goldis A, Kaimakliotis IP, Dahlerup JF, Eriksson C, Halfvarson J, Fernandez A, Hernandez V, Turcan S, Belousova E, Langholz E, Munkholm P, Odes S; Epi-IBD group.

Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30012-1. doi: 10.1016/S2468-1253(20)30012-1. [Epub ahead of print]

PMID:
32061322
2.

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.

Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ.

Clin Gastroenterol Hepatol. 2020 Jan 13. pii: S1542-3565(20)30044-6. doi: 10.1016/j.cgh.2020.01.008. [Epub ahead of print] Review.

PMID:
31945470
3.

Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study.

Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A.

J Crohns Colitis. 2020 Jan 13. pii: jjaa005. doi: 10.1093/ecco-jcc/jjaa005. [Epub ahead of print]

PMID:
31930285
4.

Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).

Capron M, Béghin L, Leclercq C, Labreuche J, Dendooven A, Standaert A, Delbeke M, Porcherie A, Nachury M, Boruchowicz A, Dupas JL, Fumery M, Paupard T, Catteau S, Deplanque D, Colombel JF, Desreumaux P.

J Clin Med. 2019 Dec 24;9(1). pii: E41. doi: 10.3390/jcm9010041.

5.

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.

Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*.

Aliment Pharmacol Ther. 2020 Mar;51(5):553-564. doi: 10.1111/apt.15609. Epub 2019 Dec 22.

PMID:
31867766
6.

Type 2 refractory celiac disease on third-generation capsule endoscopy and enteroscopy: typical appearance of ulcerative jejunitis.

Le Mouel JP, Fumery M, Hakim S, Yzet C, Dervaux A, Dray X, Nguyen-Khac E.

Endoscopy. 2019 Dec 13. doi: 10.1055/a-1046-1593. [Epub ahead of print] No abstract available.

PMID:
31858505
7.

Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease.

Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Laurent-Peyrin-Biroulet, Fumery M.

Clin Gastroenterol Hepatol. 2019 Nov 16. pii: S1542-3565(19)31312-6. doi: 10.1016/j.cgh.2019.11.025. [Epub ahead of print]

PMID:
31743755
8.

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.

Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y.

Dig Liver Dis. 2019 Nov 12. pii: S1590-8658(19)30844-8. doi: 10.1016/j.dld.2019.10.003. [Epub ahead of print]

PMID:
31732444
9.

Natural history of perianal fistulizing lesions in patients with elderly-onset Crohn's disease: a population-based study.

Danielou M, Sarter H, Pariente B, Fumery M, Ley D, Mamona C, Barthoulot M, Charpentier C, Siproudhis L, Savoye G, Gower-Rousseau C; EPIMAD Group.

J Crohns Colitis. 2019 Oct 22. pii: jjz173. doi: 10.1093/ecco-jcc/jjz173. [Epub ahead of print]

PMID:
31637413
10.

Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014).

Genin M, Fumery M, Occelli F, Savoye G, Pariente B, Dauchet L, Giovannelli J, Vignal C, Body-Malapel M, Sarter H, Gower-Rousseau C, Ficheur G.

Aliment Pharmacol Ther. 2020 Jan;51(1):139-148. doi: 10.1111/apt.15512. Epub 2019 Oct 6.

PMID:
31588597
11.

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group.

N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.

PMID:
31553834
12.

Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.

Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ.

Aliment Pharmacol Ther. 2019 Oct;50(8):848-857. doi: 10.1111/apt.15484. Epub 2019 Sep 4. Review.

PMID:
31483522
13.

Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort.

Loreau J, Duricova D, Gower-Rousseau C, Savoye G, Ganry O, Ben Khadhra H, Sarter H, Yzet C, Le Mouel JP, Kohut M, Brazier F, Chatelain D, Nguyen-Khac E, Dupas JL, Fumery M.

Clin Transl Gastroenterol. 2019 Sep;10(9):e00071. doi: 10.14309/ctg.0000000000000071.

14.

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.

Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A; POPCUR study group.

Clin Gastroenterol Hepatol. 2019 Aug 27. pii: S1542-3565(19)30916-4. doi: 10.1016/j.cgh.2019.08.041. [Epub ahead of print]

PMID:
31470175
15.

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.

Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L; PROTECT-GETAID study group.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):620-627.e1. doi: 10.1016/j.cgh.2019.05.060. Epub 2019 Jun 13.

16.

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.

Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID.

Aliment Pharmacol Ther. 2019 Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5.

PMID:
31165509
17.

Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease.

Sokol H, Brot L, Stefanescu C, Auzolle C, Barnich N, Buisson A, Fumery M, Pariente B, Le Bourhis L, Treton X, Nancey S, Allez M, Seksik P; REMIND Study Group Investigators.

Gut. 2020 Mar;69(3):462-472. doi: 10.1136/gutjnl-2019-318719. Epub 2019 May 29.

PMID:
31142586
18.

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A.

J Crohns Colitis. 2019 Sep 27;13(10):1239-1247. doi: 10.1093/ecco-jcc/jjz088.

PMID:
31056693
19.

Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease.

Hammoudi N, Cazals-Hatem D, Auzolle C, Gardair C, Ngollo M, Bottois H, Nancey S, Pariente B, Buisson A, Treton X, Fumery M, Bezault M, Seksik P, Le Bourhis L; REMIND Study Group Investigators, Flejou JF, Allez M.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):141-149.e2. doi: 10.1016/j.cgh.2019.04.045. Epub 2019 Apr 28.

PMID:
31042575
20.

Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ.

Am J Gastroenterol. 2019 Jun;114(6):1010. doi: 10.14309/ajg.0000000000000254. No abstract available.

PMID:
31033520

Supplemental Content

Loading ...
Support Center